ArticleFrontiers in medicine2024
DeepCGAN: early Alzheimer's detection with deep convolutional generative adversarial networks.
Article in Frontiers in medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Alzheimer's disease (AD) is a neurodegenerative disorder and the most prevailing cause of dementia. AD critically disturbs the daily routine, which usually needs to be detected at its early stage. Unfortunately, AD detection using magnetic resonance imaging is challenging because of the subtle physiological variations between normal and AD patients visible on magnetic resonance imaging. Methods: To cope with this challenge, we propose a deep convolutional generative adversarial network (DeepCGAN) for detecting early-stage AD in this article. The DeepCGAN is an unsupervised generative model that expands the dataset size in addition to its diversity by utilizing the generative adversarial network (GAN). The Generator of GAN follows the encoder-decoder framework and takes cognitive data as inputs, whereas the Discriminator follows a structure similar to the Generator's encoder. The last dense layer uses a softmax classifier to detect the labels indicating the AD. Results: The proposed model attains an accuracy rate of 97.32%, significantly surpassing recent state-of-the-art models' performance, including Adaptive Voting, ResNet, AlexNet, GoogleNet, Deep Neural Networks, and Support Vector Machines. Discussion: The DeepCGAN significantly improves early AD detection accuracy and robustness by enhancing the dataset diversity and leveraging advanced GAN techniques, leading to better generalization and higher performance in comparison to traditional and contemporary methods. These results demonstrate the ecacy of DeepCGAN in enhancing early AD detection, thereby potentially improving patient outcomes through timely intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.